BioNexus Gene Lab Corp (BGLC)
NASDAQ: BGLCHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BGLC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.99M
- EPS (TTM)
- -$1.26
- Dividend yield
- None
- 52-week range
- 0.621 – 4.97
- Day range
- 0.68 – 0.73
- Volume / Avg
- 3.07K / 6.70K
- Beta
- —
- Shares outstanding
- 2.93M
52-week range
BGLC stock today
BioNexus Gene Lab (BGLC) closed at $0.68 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Trading was light, with 3.07K shares changing hands, about 46% of the average daily volume. At this level, BGLC sits near the bottom of its 52-week range of $0.621 to $4.97: 86.3% below the high and 9.5% above the low.
BioNexus Gene Lab has posted a net loss over the last twelve months (EPS of -$1.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About BioNexus Gene Lab
Company profileBioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Su-Leng Tan
- Headquarters
- Kuala Lumpur
- Employees
- 19
- Website
- bionexusgenelab.com
Financial highlights
Full financialsIn fiscal 2025, BioNexus Gene Lab generated $7.4 million in revenue, down 21.9% from fiscal 2024, its first annual decline since 2024. BioNexus Gene Lab reported a net loss of $3.0 million, compared with a loss of $1.6 million a year earlier. Gross margin was 14.6% (up from 13.6%) and operating margin -39.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $7.42M | $9.51M | $9.77M | $10.93M | $13.36M |
| Growth | -21.93% | -2.66% | -10.60% | -18.21% | +17.31% |
| Net income | $-2.98M | $-1.60M | $-2.63M | $-355.97K | $751.57K |
| EPS (diluted) | — | $-0.09 | $-0.166 | — | — |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 19, 2026
- EPS actual vs est.
- $-0.39 vs —
BGLC news
All BGLC newsBioNexus Gene Lab peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ADVBAdvanced Biomed Inc. | 1.65 | -5.71% | $2.73M | vs BGLC |
| ACONAclarion Inc. | 1.22 | -13.92% | $3.52M | vs BGLC |
| AMSAmerican Shared Hospital Services | 1.00 | -4.76% | $6.67M | vs BGLC |
| MDXHMDxHealth SA | 0.1074 | -8.52% | $10.25M | vs BGLC |
| SERASera Prognostics Inc. Class A | 1.81 | -4.23% | $71.98M | vs BGLC |
| BDSXBiodesix Inc. | 7.56 | -8.92% | $83.83M | vs BGLC |
| XGNExagen Inc. | 3.61 | -5.00% | $92.10M | vs BGLC |
| KEQUKewaunee Scientific Corporation | 33.55 | -2.75% | $97.14M | vs BGLC |
Indexes, lists and sector
BioNexus Gene Lab stock FAQ
What is BioNexus Gene Lab's stock price today?
BGLC last traded at $0.68 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.
Who is BioNexus Gene Lab's CEO?
Mr. Su-Leng Tan is the chief executive officer of BioNexus Gene Lab Corp, which has about 19 employees.
What is the BGLC 52-week high?
The 52-week high for BGLC is $4.97 and the 52-week low is $0.621. The stock is currently 86.3% below its high.